Answers are grounded in this paper and cite their sources.
Xylazine exacerbates the respiratory depression induced by fentanyl. Because xylazine is a non-opioid, it is resistant to reversal by opioid receptor antagonists such as naloxone (e.g., Narcan®), thereby complicating attempts at treatment of fentanyl overdose. Antagonists of large-conductance potassium BK (big potassium) channels (BKCa) in the carotid bodies reverse drug-induced hypoxia (decreased pO2) and hypercapnia (increased pCO2). In animals and human volunteers, the selective BK antagonist ENA-001 reverses the respiratory depression induced by opioids and non-opioids, i.e., it is an "agnostic" respiratory reversal agent. Given the seriousness of xylazine plus fentanyl combination (XFC) overdose, the present pilot study in rats was designed to evaluate the potential of a single intravenous bolus of ENA-001 to mitigate the acute respiratory depression induced by a prior intravenous bolus infusion of an XFC. XFC-induced respiratory depression was manifested as a decrease in pO2 and an increase in pCO2. ENA-001, but not the vehicle, rapidly reversed these XFC-induced changes. Based on the results of this pilot study, the "agnostic" nature of ENA-001 respiratory stimulation appears to extend to XFC-induced overdose. Given the urgent clinical need, additional study seems warranted.
No takes yet. Share an insight, caveat, or question.
Miller et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: